Actively Recruiting
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
Led by KompanionCare SAS · Updated on 2026-03-09
80
Participants Needed
5
Research Sites
59 weeks
Total Duration
On this page
Sponsors
K
KompanionCare SAS
Lead Sponsor
C
Clinical Research Units Hungary
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression. The researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool. The study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance. Participants will: * Use the reminiscence app for 25 days for 10-15 minutes. * Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group. * Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).
CONDITIONS
Official Title
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women over 60 years of age.
- Diagnosis of early stage major neurocognitive disorders or mild cognitive impairment according to DSM-5.
- Mini-Mental State Exam score between 21 and 28.
- Presence of mild or moderate depression, mild or moderate apathy, or both.
- Physical and cognitive abilities sufficient to interact with the digital tool.
- Voluntary informed consent given.
- Ability to hear and see stimuli from the digital tool.
- Access to an Apple device (smartphone or tablet) running iOS 16 or higher with internet.
- At least one close referent willing to contribute biographical information via the app.
- Covered by a social security scheme.
You will not qualify if you...
- Moderate or severe dementia (MMSE score 20 or less).
- Major psychiatric disorders such as schizophrenia, severe major depression, or bipolar disorder.
- Major hearing or visual impairments.
- History of premorbid intellectual disability.
- Under guardianship, conservatorship, or legal protection.
- Prior use of the Lilia app.
- Participation in another clinical study during this study.
- New treatment for neurocognitive disorders initiated within 3 months before enrollment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
CHU Angers, Service médecine gériatrique.
Angers, France, 49 933
Actively Recruiting
2
Limoges University Hospital Center - Dupuytren Hospital], Geriatric medicine department
Limoges, France, 87042
Actively Recruiting
3
Centre Hospitalier Universitaire de Nice - Institut Claude Pompidou, Centre Mémoire de Ressources et de Recherches (CM2R)
Nice, France, 06100
Actively Recruiting
4
APHP Hôpitaux universitaires Paris centre.
Paris, France, 75013
Not Yet Recruiting
5
CHU DE TOURS, Pôle Vieillissement, Hôpital Bretonneau.
Tours, France, 37044
Actively Recruiting
Research Team
P
Peter MARKUS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here